Piper Sandler & Co’s AIM ImmunoTech AIM Stock Holding History

Piper Sandler & Co’s Portfolio AIM Stock Details AIM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	–	Sell	-1	Closed	-$9K	–	202
2014 Q3	$9K	Buy	+1	New	+$15.4K	﹤0.01%	125

Other funds holding AIM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

OAM

Occidental Asset Management Burlingame, California $844M AUM 20.95% 1-Year Est. Return

FutureAdvisor San Francisco, California $617M AUM 6.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VKH

Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BTS

BB&T Securities Richmond, Virginia $10.9B AUM 5.31% 1-Year Est. Return

Piper Sandler & Co's AIM Position: Q4 2014 in Review

Piper Sandler & Co sold out of AIM ImmunoTech (AIM) in Q4 2014, closing a stake of 1 share — an estimated $9K sold.

Piper Sandler & Co first reported a position in AIM in Q3 2014 and held it in 1 quarter. The position peaked at $9K in Q3 2014. 13 funds tracked by Wall St. Rank hold AIM as of Q4 2014.

Piper Sandler & Co reported no remaining AIM ImmunoTech position as of Q4 2014 after selling out during the quarter.
Piper Sandler & Co sold 1 AIM ImmunoTech share in Q4 2014, an estimated $9K.
Piper Sandler & Co first reported a position in AIM ImmunoTech in Q3 2014 and held it in 1 quarter.
Piper Sandler & Co's AIM ImmunoTech position peaked at $9K in Q3 2014.
13 funds tracked by Wall St. Rank held AIM ImmunoTech as of Q4 2014.

Based on Piper Sandler & Co's 13F filing for Q4 2014, filed 17 Feb 2015.